Search…

Lates News

23/09/2025

In the morning of September 23, Kolonbo Shengwu announced on the Hong Kong Stock Exchange that the new drug application (NDA) for the rearranged during transfection (RET) small molecule kinase inhibitor project A400 (also known as EP0031) has been accepted by the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for the treatment of RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients.

Latest

2 m ago

Data element sector undergoes significant adjustments, with Shanghai Wumao hitting the limit down.

4 m ago

Hong Kong stocks abnormal movement | Gold stocks continue to rise, spot gold continues to refresh its high, the market expects a clear prospect of interest rate cuts.

5 m ago

Japanese Prime Minister candidate Junichiro Koizumi: We should utilize the expected increase in tax revenue and the funds obtained from reducing expenses to provide financial support for measures to address the rising cost of living.

5 m ago

Hong Kong stock market anomaly | Datang Gold (08299.HK) jumped more than 15% in early trading, raising over HK$270 million in share placement. The controlling shareholder of Wanjin Gold Group will become the second largest shareholder.

5 m ago

Precious metals sector fluctuates and rises, Xiaocheng Technology's stock increased by over 8%.

See all latest